Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds -- to counter key symptoms of COVID-19. "Drug AI helps find that needle in the haystack, and we are optimistic that we have found four of them to start," said Aris Persidis, Biovista's President and Co-Founder. The first drug has the potential to reduce viral replication, limit inflammatory events, and help protect against acute lung injury. The second drug has the potential to reduce viral load, improving the primary ARDS component of the disease and reducing the cytokine storm in COVID-19. "These compounds won't cure COVID-19, but appear able, based on their mechanism of action, to limit the damage," said Dr. Eftychia Lekka, Senior Investigator, Drug Discovery.

With new hardware, software, and services optimized for AI and high performance computing (HPC), HPE wants to make it faster and easier for businesses and scientific organizations to use data-based insights to drive innovation. The HPE Apollo 6000 Gen10 System is the "most secure HPC system in the world," the release said, and it has been re-tooled to be able to provide more than 300 teraflops per rack. The HPE Apollo sx40 System and the HPE Apollo pc40 System are both Intel Xeon Gen10 servers, with support for different kinds of GPUs. The new experience brings boosted firmware security, performance software from HPE, cluster management, and additional service enhancements that will make it simpler for businesses to derive value from their AI tools.